Earum Pharmaceuticals has informed that there is misprint on page no 40 under the heading of Minimum Subscription in letter of offer dated April 19, 2023, the misprinting is in regards to the applicability of Minimum Subscription, which states that the requirement of minimum subscription in the Issue shall be applicable. Further, it stated that same is not applicable as it is satisfying both the conditions; if object of the issue involves financing other than financing of capital expenditure for a project and; its Promoter Bhumishth Patel, vide letter dated 24th January, 2023 has given intend to fully subscribe to their portion of rights entitlement not renounce their rights except to the extent of renunciation within the promoter group. Accordingly, in terms of Regulation 86(2) of the SEBI ICDR Regulations, is not applicable to the Issue.
The above information is a part of company’s filings submitted to BSE.
